Sublingual immunotherapy not effective in house dust mite-allergic children in primary care

Pediatric Allergy and Immunology

Volumn 23, Issue 2, 2012, Pages 151-159

  de Bot, Cindy M A ^a   Moed, Heleen ^a   Berger, Marjolein Y ^a,b   Röder, Esther ^a   Hop, Wim C J ^a   de Groot, Hans ^c   de Jongste, Johan C ^d   Gerth van Wijk, Roy ^a   Bindels, Patrick J E ^a   van der Wouden, Johannes C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c REINIER DE GRAAF HOSPITAL   (Netherlands)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Adolescent; Allergic rhinitis; Child; House dust mite; Immunotherapy; Primary care; Sublingual

Indexed keywords

IMMUNOLOGIC AGENT; ORALGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; AUTUMN; CHILD; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ECZEMA; FEMALE; HOUSE DUST ALLERGY; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCHOOL CHILD; SUBLINGUAL IMMUNOTHERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; WHEEZING;

EID: 84858795651     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2011.01219.x     Document Type: Article

References (54)

1. Druce H. Allergic and nonallergic rhinitis. In: Middleton E Jr, Reed CE, Ellis NF, Adkinson NF Jr, Yunginger JW, Busse WW, eds. Allergy: Priciples and Practice, 4th edn. St. Louis: Mosby, 1993: 1433-55.
2. Mygind N, Maclerio R. Definition, classification and terminology. In: Mygind NN, ed. Allergic and Non-Allergic Rhinitis. Copenhagen: Munksgaard, 1993: 11-4.
3. Corbach M, Jung H, Toorenburg-Beijer B, et al. NHG-Standaard Allergische en hyperreactieve rhinitis. Huisarts en Wetenschap 1995: 38: 216-27.
4. Sachs A, Berger MY, Lucassen PLBJ, van der Wal J, van Balen J, Verduijn M. Allergische en niet-allergische rhinitis M48 Eerste herziening. Huisarts en Wetenschap 2006: 49: 254-65.
5. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001: 108: S147-334.
6. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008: 63: 8-160.
7. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998: 102: 558-62.
8. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001: 87: 47-55.
9. Bernstein DI, Wanner M, Borish L, Liss GM, Immunotherapy Committee, American Academy of Allergy Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004: 113: 1129-36.
10. Andre C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000: 121: 229-34.
11. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs 2003: 5: 777-81.
12. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7years. Ann Allergy Asthma Immunol 2005: 95: 254-8.
13. Rienzo VD, Minelli M, Musarra A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5years. Clin Exp Allergy 2005: 35: 560-4.
14. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001: 31: 1392-7.
15. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002: 109: 251-6.
16. Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006: 61: 855-9.
17. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007: 62: 943-8.
18. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008: 101: 206-11.
19. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000: 55: 842-9.
20. Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006: 100: 1374-83.
21. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009: 123: 167-73 e7.
22. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009: 123: 160-6 e3.
23. Röder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007: 119: 892-8.
24. Malling HJ. Is sublingual immunotherapy clinically effective? Curr Opin Allergy Clin Immunol 2002: 2: 523-31.
25. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010: (12): CD002893.
26. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006: 97: 141-8.
27. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA(2)LEN meta-analysis. Allergy 2009: 64: 1570-9.
28. de Bot CM, Moed H, Berger MY, et al. Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment. BMC Fam Pract 2008: 9: 59.
29. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994: 93: 413-23.
30. Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol 1998: 101: 163-70.
31. Malling HJ. Methodology and quality of immunotherapy trials. Allergy 2004: 59: 482-4.
32. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007: 62: 317-24.
33. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009: 64: 1-59.
34. Committee for Medicinal Products for Human Use (CHMP) and Efficacy Working Party (EWP) Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases: CHMP/EWP/18504/2006, 2008.
35. Sidenius KE, Hallas TE, Poulsen LK, Mosbech H. A controlled intervention study concerning the effect of intended temperature rise on house dust mite load. Ann Agric Environ Med 2002: 9: 163-8.
36. van der Heide S, De Monchy JG, De Vries K, Dubois AE, Kauffman HF. Seasonal differences in airway hyperresponsiveness in asthmatic patients: relationship with allergen exposure and sensitization to house dust mites. Clin Exp Allergy 1997: 27: 627-33.
37. van der Heide S, de Monchy JG, de Vries K, Bruggink TM, Kauffman HF. Seasonal variation in airway hyperresponsiveness and natural exposure to house dust mite allergens in patients with asthma. J Allergy Clin Immunol 1994: 93: 470-5.
38. Ciprandi G, Cadario G, Di Gioacchino GM, et al. Sublingual immunotherapy in children with allergic polysensitization. Allergy Asthma Proc 2010: 31: 227-31.
39. Marogna M, Spadolini I, Massolo A, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol 2007: 98: 274-80.
40. Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy 2010: 65: 668-9.
41. Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997: 8: 21-7.
42. Bahceciler NN, Isik U, Barlan IB, Basaran N. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001: 32: 49-55.
43. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007: 18: 47-57.
44. Röder E, Berger MY, de Groot H, et al. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol 2008: 119: 892-8.
45. Larenas-Linnemann D. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Curr Opin Allergy Clin Immunol 2009: 9: 168-76.
46. Van Hoecke H, Vastesaeger N, Dewulf L, Sys L, van Cauwenberge P. Classification and management of allergic rhinitis patients in general practice during pollen season. Allergy 2006: 61: 705-11.
47. Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006: 117: 158-62.
48. Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010: 40: 922-32.
49. Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006: 61: 1177-83.
50. Rask C, Brimnes J, Lund K. Shorter dosing intervals of sublingual immunotherapy lead to more efficacious treatment in a mouse model of allergic inflammation. Scand J Immunol 2010: 71: 403-12.
51. Durham SR, Birk AO, Andersen JS. Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials. Allergy 2010: 66: 120-3.
52. Ryan D, Grant-Casey J, Scadding G, Pereira S, Pinnock H, Sheikh A. Management of allergic rhinitis in UK primary care: baseline audit. Prim Care Respir J 2005: 14: 204-9.
53. Ryan D, van Weel C, Bousquet J, et al. Primary care: the cornerstone of diagnosis of allergic rhinitis. Allergy 2008: 63: 981-9.
54. Costa DJ, Bousquet PJ, Ryan D, et al. Guidelines for allergic rhinitis need to be used in primary care. Prim Care Respir J 2009: 18: 250-7.